Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982670 | 1.00 | NAAA (0.71) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL2843459 | 0.98 | NAAA (0.68) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL4985814 | 0.98 | NAAA (0.68) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4933082 | 0.97 | NAAA (0.67) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4933073 | 0.97 | NAAA (0.67) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL4986402 | 0.94 | NAAA (0.61) | NAAALMNAPAX8HTTKDM4A | |
| SCHEMBL5664082 | 0.89 | NAAA (0.61) | NAAALMNAPAX8EPHX1ALDH1A1 | |
| SCHEMBL4201389 | 0.87 | NAAA (0.53) | NAAALMNAPAX8KDM4A | |
| SCHEMBL4982177 | 0.86 | NAAA (0.52) | NAAAKDM4A | |
| Hydrochloric Acid SCHEMBL4199636 | 0.86 | NAAA (0.51) | NAAALMNAPAX8KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | PLPBP, ECE1, MCU | NAAA 3203/4885LMNA 1154/4885PAX8 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.